Common TitleCAPELLA
Official Title A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS-6207 in Combination With an Optimized Background Regimen in Heavily Treatment Experienced People Living With HIV-1 Infection With Multidrug Resistance
Phase Phase III
ClinicalTrials.gov NCT04150068
Treatments
Lenacapavir
Lenacapavir
Tradename:SunlencaClass:Capsid InhibitorsCategories Treatment-Experienced
Funding
IndustryGilead Sciences
References
- Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022;386:1793-1803.